Overview

Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation

Status:
Completed
Trial end date:
2021-07-15
Target enrollment:
Participant gender:
Summary
RuxCoFlam is a single arm, non-randomized open phase II trial for front line treatment of Covid-19 patients with defined hyperinflammation.
Phase:
Phase 2
Details
Lead Sponsor:
Prof. Dr. med. Andreas Hochhaus
University of Jena